Diphtheria fusion protein therapy of chemoresistant malignancies

Arthur E. Frankel, Patrick Rossi, Timothy M. Kuzel, Francine Foss

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Patients with widespread cancer respond initially to combination chemotherapy, immunotherapy, and/or radiotherapy, but most relapse with chemoresistant disease. Novel methods of killing resistant neoplastic stem cells are needed. One such approach is therapy with targeted toxins composed of tumor cell selective ligands covalently linked to group I peptide toxins (group II and III peptide toxins act on the cell surface). The targeted toxin is delivered to the cell by a tumor selective ligand. Once bound, the ligand-receptor complex is internalized. The catalytic domain escapes to the cytosol. The toxin then enzymatically modifies a critical cell function (protein synthesis, p21 Rho activity, protein kinase signaling, cyclic AMP signaling or others). The irreversibly damaged cells fails to divide and, eventually, undergoes lysis or programmed cell death. Targeted peptide toxins used to date in the treatment of chemotherapy refractory cancers include ricin toxin, Pseudomonas exotoxin, pokeweed antiviral protein, saporin, gelonin and diphtheria toxin. In this review, we have focused on the applications of genetically engineered diphtheria toxin for cancer therapy.

Original languageEnglish (US)
Pages (from-to)19-36
Number of pages18
JournalCurrent Cancer Drug Targets
Volume2
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Diphtheria
Immunotoxins
Diphtheria Toxin
Neoplasms
Ligands
Proteins
Peptides
Therapeutics
Ricin
Exotoxins
rho GTP-Binding Proteins
Neoplastic Stem Cells
Pseudomonas
Combination Drug Therapy
Cyclic AMP
Cytosol
Immunotherapy
Protein Kinases
Catalytic Domain
Cell Death

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Cancer Research

Cite this

Diphtheria fusion protein therapy of chemoresistant malignancies. / Frankel, Arthur E.; Rossi, Patrick; Kuzel, Timothy M.; Foss, Francine.

In: Current Cancer Drug Targets, Vol. 2, No. 1, 2002, p. 19-36.

Research output: Contribution to journalArticle

Frankel, Arthur E. ; Rossi, Patrick ; Kuzel, Timothy M. ; Foss, Francine. / Diphtheria fusion protein therapy of chemoresistant malignancies. In: Current Cancer Drug Targets. 2002 ; Vol. 2, No. 1. pp. 19-36.
@article{ab8bd640c8e247bda053881f631c003d,
title = "Diphtheria fusion protein therapy of chemoresistant malignancies",
abstract = "Patients with widespread cancer respond initially to combination chemotherapy, immunotherapy, and/or radiotherapy, but most relapse with chemoresistant disease. Novel methods of killing resistant neoplastic stem cells are needed. One such approach is therapy with targeted toxins composed of tumor cell selective ligands covalently linked to group I peptide toxins (group II and III peptide toxins act on the cell surface). The targeted toxin is delivered to the cell by a tumor selective ligand. Once bound, the ligand-receptor complex is internalized. The catalytic domain escapes to the cytosol. The toxin then enzymatically modifies a critical cell function (protein synthesis, p21 Rho activity, protein kinase signaling, cyclic AMP signaling or others). The irreversibly damaged cells fails to divide and, eventually, undergoes lysis or programmed cell death. Targeted peptide toxins used to date in the treatment of chemotherapy refractory cancers include ricin toxin, Pseudomonas exotoxin, pokeweed antiviral protein, saporin, gelonin and diphtheria toxin. In this review, we have focused on the applications of genetically engineered diphtheria toxin for cancer therapy.",
author = "Frankel, {Arthur E.} and Patrick Rossi and Kuzel, {Timothy M.} and Francine Foss",
year = "2002",
doi = "10.2174/1568009023333944",
language = "English (US)",
volume = "2",
pages = "19--36",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Diphtheria fusion protein therapy of chemoresistant malignancies

AU - Frankel, Arthur E.

AU - Rossi, Patrick

AU - Kuzel, Timothy M.

AU - Foss, Francine

PY - 2002

Y1 - 2002

N2 - Patients with widespread cancer respond initially to combination chemotherapy, immunotherapy, and/or radiotherapy, but most relapse with chemoresistant disease. Novel methods of killing resistant neoplastic stem cells are needed. One such approach is therapy with targeted toxins composed of tumor cell selective ligands covalently linked to group I peptide toxins (group II and III peptide toxins act on the cell surface). The targeted toxin is delivered to the cell by a tumor selective ligand. Once bound, the ligand-receptor complex is internalized. The catalytic domain escapes to the cytosol. The toxin then enzymatically modifies a critical cell function (protein synthesis, p21 Rho activity, protein kinase signaling, cyclic AMP signaling or others). The irreversibly damaged cells fails to divide and, eventually, undergoes lysis or programmed cell death. Targeted peptide toxins used to date in the treatment of chemotherapy refractory cancers include ricin toxin, Pseudomonas exotoxin, pokeweed antiviral protein, saporin, gelonin and diphtheria toxin. In this review, we have focused on the applications of genetically engineered diphtheria toxin for cancer therapy.

AB - Patients with widespread cancer respond initially to combination chemotherapy, immunotherapy, and/or radiotherapy, but most relapse with chemoresistant disease. Novel methods of killing resistant neoplastic stem cells are needed. One such approach is therapy with targeted toxins composed of tumor cell selective ligands covalently linked to group I peptide toxins (group II and III peptide toxins act on the cell surface). The targeted toxin is delivered to the cell by a tumor selective ligand. Once bound, the ligand-receptor complex is internalized. The catalytic domain escapes to the cytosol. The toxin then enzymatically modifies a critical cell function (protein synthesis, p21 Rho activity, protein kinase signaling, cyclic AMP signaling or others). The irreversibly damaged cells fails to divide and, eventually, undergoes lysis or programmed cell death. Targeted peptide toxins used to date in the treatment of chemotherapy refractory cancers include ricin toxin, Pseudomonas exotoxin, pokeweed antiviral protein, saporin, gelonin and diphtheria toxin. In this review, we have focused on the applications of genetically engineered diphtheria toxin for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036286543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036286543&partnerID=8YFLogxK

U2 - 10.2174/1568009023333944

DO - 10.2174/1568009023333944

M3 - Article

C2 - 12188918

AN - SCOPUS:0036286543

VL - 2

SP - 19

EP - 36

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 1

ER -